We are committed to patients with hemophilia and the bleeding disorders community.

Ongoing focus.

Two buildings icon

At Novo Nordisk, we believe that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way.

Product portfolio.

Vials icon

We aspire to be a respected leader in the health care industry, helping patients with treatments for:

  • FVII deficiency
  • FVIII deficiency
  • FVIII deficiency with inhibitors
  • FIX deficiency
  • FIX deficiency with inhibitors
  • FXIII deficiency
  • Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
  • Acquired hemophilia

Environmental awareness.

Tree icon

We also strive to minimize the environmental impact of our activities. Our facilities in Denmark supply quality products in a socially responsible and environmentally sound way, using 100% renewable energy.

The Triple Bottom Line.

The Triple Bottom Line (TBL) is Novo Nordisk’s way of doing business. We believe that a healthy economy, environment, and society are fundamental to long-term business success. We are one of only four companies in the world who have incorporated our philosophy into our company bylaws.

Everything we do and every decision we make is informed by the three pillars of TBL:

Social impact.

Social responsibility is about caring for people. This applies to the people who depend on our products, as well as to our employees. We work to continuously integrate social, health, and safety considerations into our daily business.


Environmental responsibility.

Environmental soundness addresses our impact on the external environment – and we've taken a concerted approach to ensure that our efforts to be green pay off.

The campus of our LEED Silver certified U.S. Headquarters demonstrates our approach to being responsible stewards of our environment, driven by the company’s commitment to help people live healthy lives, and consistent with Novo Nordisk's TBL business model.

Our campus utilized recycled and locally-sourced materials, and is fully powered by renewable energy from wind, solar, and hydro sources—a feature that is expected to lead to a 30 percent reduction in energy costs.


Financial performance

Economic viability is about managing the business in a way that secures growth and value creation, and delivers competitive performance in these areas. Investing in our employees contributes to our award-winning workplace and supports our goal of delivering innovative achievements.

As of August 2017, Novo Nordisk Inc. has been ranked in Fortune Magazine's Best Places to Work listing every year since 2009. Most recently, Novo Nordisk was presented with the New Good Neighbor Award by the New Jersey Business & Industry Association. This award was based on a variety of factors, including economic benefit/job creation, architectural merit, and community involvement.

Novo Nordisk is also committed to investing in Research and Development. In 2016, 13% of sales went towards funding R&D projects across the organization.

STAY IN THE KNOW. SIGN UP TO GET THE LATEST UPDATES ON REBINYN®

STAY IN THE KNOW. SIGN UP TO GET THE LATEST UPDATES ON REBINYN®

Selected Important Safety Information

What is the most important information I need to know about Rebinyn®?

  • Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center. Carefully follow your healthcare provider’s instructions regarding the dose and schedule for infusing Rebinyn®.

Who should not use Rebinyn®?
Do not use Rebinyn® if you:

  • are allergic to Factor IX or any of the other ingredients of Rebinyn®.
  • are allergic to hamster proteins.
     

Indications and Usage

What is Rebinyn® Coagulation Factor IX (Recombinant), GlycoPEGylated?
Rebinyn® is an injectable medicine used to replace clotting Factor IX that is missing in patients with hemophilia B. Rebinyn® is used to treat and control bleeding in people with hemophilia B. Your healthcare provider may give you Rebinyn® when you have surgery. Rebinyn® is not used for routine prophylaxis or for immune tolerance therapy.
 

Important Safety Information

What is the most important information I need to know about Rebinyn®?

  • Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center. Carefully follow your healthcare provider’s instructions regarding the dose and schedule for infusing Rebinyn®.

Who should not use Rebinyn®?
Do not use Rebinyn® if you:

  • are allergic to Factor IX or any of the other ingredients of Rebinyn®.
  • are allergic to hamster proteins.

What should I tell my healthcare provider before using Rebinyn®?
Tell your healthcare provider if you:

  • have or have had any medical conditions.
  • take any medicines, including non-prescription medicines and dietary supplements.
  • are nursing, pregnant, or plan to become pregnant.
  • have been told you have inhibitors to Factor IX.

How should I use Rebinyn®?

  • Rebinyn® is given as an infusion into the vein.
  • Call your healthcare provider right away if your bleeding does not stop after taking Rebinyn®.
  • Do not stop using Rebinyn® without consulting your healthcare provider.

What are the possible side effects of Rebinyn®?

  • Common side effects include swelling, pain, rash or redness at the location of the infusion, and itching.
  • Call your healthcare provider right away or get emergency treatment right away if you get any of the following signs of an allergic reaction: hives, chest tightness, wheezing, difficulty breathing, and/or swelling of the face.
  • Tell your healthcare provider about any side effect that bothers you or that does not go away.
  • Animals given repeat doses of Rebinyn® showed Polyethylene Glycol (PEG) inside cells lining blood vessels in the choroid plexus, which makes the fluid that cushions the brain. The potential human implications of these animal tests are unknown.
     

Please click here for Prescribing Information.

Rebinyn® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.